MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597388 | Name: Protein kinase inhibitor peptide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Protein kinase inhibitor peptide corresponds to the inhibitory domain of the heat-stable protein kinase inhibitor.

Chemical Structure

Protein kinase inhibitor peptide
Protein kinase inhibitor peptide
CAS#128022-93-5

Theoretical Analysis

MedKoo Cat#: 597388

Name: Protein kinase inhibitor peptide

CAS#: 128022-93-5

Chemical Formula: C84H136N28O27

Exact Mass: 1969.0130

Molecular Weight: 1970.18

Elemental Analysis: C, 51.21; H, 6.96; N, 19.91; O, 21.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Protein kinase inhibitor peptide; PKIP;
IUPAC/Chemical Name
L-Isoleucine, L-threonyl-L-threonyl-L-tyrosyl-L-alanyl-L-alpha-aspartyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-serylglycyl-L-arginyl-L-threonylglycyl-L-arginyl-L-arginyl-L-asparaginyl-L-alanyl-
InChi Key
ZLKNTGQAQQSIFV-HQAKDUOCSA-N
InChi Code
InChI=1S/C84H136N28O27/c1-11-38(3)62(109-76(133)53(31-46-19-14-13-15-20-46)105-75(132)55(34-60(121)122)104-66(123)40(5)98-73(130)52(32-47-24-26-48(117)27-25-47)107-80(137)65(45(10)116)112-77(134)61(86)43(8)114)79(136)100-41(6)67(124)108-56(37-113)69(126)96-35-58(119)102-50(22-17-29-94-83(89)90)72(129)111-64(44(9)115)78(135)97-36-59(120)101-49(21-16-28-93-82(87)88)70(127)103-51(23-18-30-95-84(91)92)71(128)106-54(33-57(85)118)74(131)99-42(7)68(125)110-63(81(138)139)39(4)12-2/h13-15,19-20,24-27,38-45,49-56,61-65,113-117H,11-12,16-18,21-23,28-37,86H2,1-10H3,(H2,85,118)(H,96,126)(H,97,135)(H,98,130)(H,99,131)(H,100,136)(H,101,120)(H,102,119)(H,103,127)(H,104,123)(H,105,132)(H,106,128)(H,107,137)(H,108,124)(H,109,133)(H,110,125)(H,111,129)(H,112,134)(H,121,122)(H,138,139)(H4,87,88,93)(H4,89,90,94)(H4,91,92,95)/t38-,39-,40-,41-,42-,43+,44+,45+,49-,50-,51-,52-,53-,54-,55-,56-,61-,62-,63-,64-,65-/m0/s1
SMILES Code
CC[C@H](C)[C@@H](C(O)=O)NC([C@H](C)NC([C@H](CC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC(CNC([C@H]([C@H](O)C)NC([C@H](CCCNC(N)=N)NC(CNC([C@H](CO)NC([C@H](C)NC([C@H]([C@@H](C)CC)NC([C@H](CC1=CC=CC=C1)NC([C@H](CC(O)=O)NC([C@H](C)NC([C@H](CC2=CC=C(O)C=C2)NC([C@H]([C@H](O)C)NC([C@H]([C@H](O)C)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,970.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dalton GD, Dewey WL. Protein kinase inhibitor peptide (PKI): a family of endogenous neuropeptides that modulate neuronal cAMP-dependent protein kinase function. Neuropeptides. 2006 Feb;40(1):23-34. Epub 2006 Jan 26. Review. PubMed PMID: 16442618. 2: Olah GA, Mitchell RD, Sosnick TR, Walsh DA, Trewhella J. Solution structure of the cAMP-dependent protein kinase catalytic subunit and its contraction upon binding the protein kinase inhibitor peptide. Biochemistry. 1993 Apr 13;32(14):3649-57. PubMed PMID: 8385485. 3: Taffs RE, Sitkovsky MV. Modulation of the effector functions of cytolytic T-lymphocytes with synthetic peptide inhibitors of protein kinases. J Pharm Sci. 1992 Jan;81(1):37-44. PubMed PMID: 1619567. 4: Glass DB, Feller MJ, Levin LR, Walsh DA. Structural basis for the low affinities of yeast cAMP-dependent and mammalian cGMP-dependent protein kinases for protein kinase inhibitor peptides. Biochemistry. 1992 Feb 18;31(6):1728-34. PubMed PMID: 1310617. 5: Godwin AJ, Green LM, Walsh MP, McDonald JR, Walsh DA, Fletcher WH. In situ regulation of cell-cell communication by the cAMP-dependent protein kinase and protein kinase C. Mol Cell Biochem. 1993 Nov;127-128:293-307. PubMed PMID: 7935358. 6: Olsen SR, Uhler MD. Affinity purification of the C alpha and C beta isoforms of the catalytic subunit of cAMP-dependent protein kinase. J Biol Chem. 1989 Nov 5;264(31):18662-6. PubMed PMID: 2553718. 7: Kurokawa H, Kato K, Iwanaga T, Sugi T, Sudo A, Kobayashi K, Gong H, Takemae H, Recuenco FC, Horimoto T, Akashi H. Identification of Toxoplasma gondii cAMP dependent protein kinase and its role in the tachyzoite growth. PLoS One. 2011;6(7):e22492. doi: 10.1371/journal.pone.0022492. Epub 2011 Jul 20. PubMed PMID: 21799871; PubMed Central PMCID: PMC3140512. 8: Ruth P, Kamm S, Nau U, Pfeifer A, Hofmann F. A cGMP kinase mutant with increased sensitivity to the protein kinase inhibitor peptide PKI(5-24). Biol Chem. 1996 Jul-Aug;377(7-8):513-20. PubMed PMID: 8922286. 9: Fernandez A, Mery J, Vandromme M, Basset M, Cavadore JC, Lamb NJ. Effective intracellular inhibition of the cAMP-dependent protein kinase by microinjection of a modified form of the specific inhibitor peptide PKi in living fibroblasts. Exp Cell Res. 1991 Aug;195(2):468-77. PubMed PMID: 2070829. 10: Zimmermann LJ, Lee WS, Smith BT, Post M. Cyclic AMP-dependent protein kinase does not regulate CTP:phosphocholine cytidylyltransferase activity in maturing type II cells. Biochim Biophys Acta. 1994 Feb 10;1211(1):44-50. PubMed PMID: 8123681. 11: Shalaby T, Liniger M, Seebeck T. The regulatory subunit of a cGMP-regulated protein kinase A of Trypanosoma brucei. Eur J Biochem. 2001 Dec;268(23):6197-206. PubMed PMID: 11733015. 12: Steichen JM, Iyer GH, Li S, Saldanha SA, Deal MS, Woods VL Jr, Taylor SS. Global consequences of activation loop phosphorylation on protein kinase A. J Biol Chem. 2010 Feb 5;285(6):3825-32. doi: 10.1074/jbc.M109.061820. Epub 2009 Dec 4. PubMed PMID: 19965870; PubMed Central PMCID: PMC2823524. 13: Amato SF, Nakajima K, Hirano T, Chiles TC. Transcriptional regulation of the junB gene in B lymphocytes: role of protein kinase A and a membrane Ig-regulated protein phosphatase. J Immunol. 1997 Nov 15;159(10):4676-85. PubMed PMID: 9366390. 14: Schwartz RD, Heuschneider G, Edgar PP, Cohn JA. cAMP analogs inhibit gamma-aminobutyric acid-gated chloride flux and activate protein kinase A in brain synaptoneurosomes. Mol Pharmacol. 1991 Mar;39(3):370-5. PubMed PMID: 1848658. 15: Porter NM, Twyman RE, Uhler MD, Macdonald RL. Cyclic AMP-dependent protein kinase decreases GABAA receptor current in mouse spinal neurons. Neuron. 1990 Dec;5(6):789-96. PubMed PMID: 2176510. 16: Fujita A, Takeuchi T, Nakajima H, Nishio H, Hata F. Involvement of heterotrimeric GTP-binding protein and rho protein, but not protein kinase C, in agonist-induced Ca2+ sensitization of skinned muscle of guinea pig vas deferens. J Pharmacol Exp Ther. 1995 Jul;274(1):555-61. PubMed PMID: 7616445. 17: Smith BL, Mochly-Rosen D. Inhibition of protein kinase C function by injection of intracellular receptors for the enzyme. Biochem Biophys Res Commun. 1992 Nov 16;188(3):1235-40. PubMed PMID: 1332715. 18: Li H, Liu JP, Smith R, Robinson PJ. Identification of cGMP-dependent protein kinase and its specific substrates in the anterior pituitary. Mol Cell Endocrinol. 1996 Sep 18;122(2):159-71. PubMed PMID: 8902846. 19: Massaad C, Houard N, Lombès M, Barouki R. Modulation of human mineralocorticoid receptor function by protein kinase A. Mol Endocrinol. 1999 Jan;13(1):57-65. PubMed PMID: 9892012. 20: Mujtaba MG, Flowers LO, Patel CB, Patel RA, Haider MI, Johnson HM. Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form. J Immunol. 2005 Oct 15;175(8):5077-86. PubMed PMID: 16210611.